These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29472747)

  • 1. Lercanidipine in the Management of Hypertension: An Update.
    Grassi G; Robles NR; Seravalle G; Fici F
    J Pharmacol Pharmacother; 2017; 8(4):155-165. PubMed ID: 29472747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
    Makarounas-Kirchmann K; Glover-Koudounas S; Ferrari P
    Clin Ther; 2009 Aug; 31(8):1652-63. PubMed ID: 19808126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lercanidipine: a novel dihydropyridine calcium-channel blocker.
    Epstein M
    Heart Dis; 2001; 3(6):398-407. PubMed ID: 11975824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension, possible vascular protection and lercanidipine.
    Ram CV
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):783-8. PubMed ID: 17173495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
    Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lercanidipine in the treatment of hypertension.
    Beckey C; Lundy A; Lutfi N
    Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lercanidipine: a review of its use in hypertension.
    McClellan KJ; Jarvis B
    Drugs; 2000 Nov; 60(5):1123-40. PubMed ID: 11129125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM; Chapman TM; Goa KL
    Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lercanidipine in hypertension.
    Borghi C
    Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
    Menne J; Park JK; Agrawal R; Lindschau C; Kielstein JT; Kirsch T; Marx A; Muller D; Bahlmann FH; Meier M; Bode-Böger SM; Haller H; Fliser D
    FASEB J; 2006 May; 20(7):994-6. PubMed ID: 16597674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection with calcium antagonists: the role of lercanidipine.
    Burnier M
    Curr Med Res Opin; 2013 Dec; 29(12):1727-35. PubMed ID: 24069902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of existing and newer calcium channel blockers in the treatment of hypertension.
    Basile J
    J Clin Hypertens (Greenwich); 2004 Nov; 6(11):621-29; quiz 630-1. PubMed ID: 15538095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
    Leonetti G; Magnani B; Pessina AC; Rappelli A; Trimarco B; Zanchetti A;
    Am J Hypertens; 2002 Nov; 15(11):932-40. PubMed ID: 12441211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study.
    Cheng KH; Cheng KC; Cheng KY; Yang YH; Lee CW; Lai WT
    Curr Med Res Opin; 2017 Jun; 33(6):1111-1117. PubMed ID: 28300435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable?
    Elliott HL; Meredith PA
    World J Cardiol; 2014 Jun; 6(6):507-13. PubMed ID: 24976923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
    Cleophas TJ; van Ouwerkerk BM; van der Meulen J; Zwinderman AH
    Angiology; 2001 Jul; 52(7):469-75. PubMed ID: 11515986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.
    Borghi C; Prandin MG; Dormi A; Ambrosioni E;
    Blood Press Suppl; 2003 May; 1():14-21. PubMed ID: 12800983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.